14天12板！603122，明日复牌！

Core Viewpoint - The company, HeFu China (603122), will resume trading on November 20, 2025, after completing an investigation into abnormal stock price fluctuations, confirming that its business operations remain normal and no significant changes have occurred in its internal or external environment [1][2]. Group 1: Stock Trading and Market Performance - The company's stock experienced a significant increase, with a cumulative rise of 256.29% over 14 trading days, including 12 days closing at the daily limit price, which is substantially higher than the industry and Shanghai Composite Index performance [2]. - The stock has faced 5 instances of abnormal fluctuations and 3 instances of severe fluctuations during this period, indicating potential market overheating and irrational speculation risks [2]. Group 2: Financial Performance - The company reported a net profit attributable to shareholders of -5.048 million yuan for Q3 2025, primarily due to changes in domestic macroeconomic conditions and price reductions from centralized procurement policies in the medical industry, leading to decreased sales revenue and profit levels [4]. - The company's operating revenue for the current reporting period was 181.204 million yuan, reflecting a year-on-year decrease of 21.27%, while the total profit was -5.437 million yuan, down 193.80% compared to the previous year [5]. - The static price-to-earnings (P/E) ratio of the company is 343.67 times, significantly higher than the industry average P/E ratio of 30.94 times, indicating a substantial deviation from reasonable valuation levels [5].